A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia
← catalyst calendarNCT06073860 · readout in 488 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
104estimated
Sites
2
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-25 | actual | When the study began enrolling |
| Primary completion | 2027-12-21 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-21 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-11-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Myelodysplastic Syndrome
- Beta Thalassemia
Intervention
- Drug: Luspatercept
Primary outcome
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured Up to 6 months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed